Entry Rationale
The current price of $7.45 is close to the 20-day support level of $7.20. Therefore, trusting the defense around the support level, I will consider entering with the aim of a short-term rebound toward the resistance level of $8.65.
Verastem Oncology jumps after pricing $250M securities offering
Shares of Verastem Oncology surged after pricing a $250 million securities offering.
The current price of $7.45 is close to the 20-day support level of $7.20. Therefore, trusting the defense around the support level, I will consider entering with the aim of a short-term rebound toward the resistance level of $8.65.
If the price holds above the $7.20 support level from the current price of $7.45, I will attempt scaled profit-taking toward the $8.65 resistance level. However, if it breaks below the $7.20 support level, I will execute an immediate stop-loss.
RSI (14) stands at 39.7, indicating a neutral to weak phase, moving averages are in a bullish alignment (stacked in ascending order), trading volume is at 1.34 times the 20-day average, and the 7-day volatility (rate of change) has recorded -3.2%.
Initially, we entered with the target of a short-term rebound toward the $8.65 resistance level, trusting the defense around the $20 support level on the 20th. However, the actual outcome far exceeded the projected return of 4.5%, recording a 23.9% surge and receiving an "OVERHIT" rating. Despite conservative factors such as the risk of equity dilution via the 424B5 filing following the pricing news of a $250 million securities offering, and a CRITICAL alert level, accompanied by 1.34x volume, the stock easily broke through the $8.65 resistance level, leading to a sharp rally.
While the CRITICAL alert rating and equity dilution risk immediately following a large-scale public offering disclosure serve as strong grounds for a conservative response, we confirmed that during a trend-reversal phase accompanied by trading volume, short-term resistance lines can be broken much more strongly than expected. When similar offering issues arise in the future, we will maintain strict risk management while adopting the strategic flexibility to flexibly upwardly adjust target prices if increased volume and support-level defense coincide.